Bush K - Search Results

1

Critical analysis of antibacterial agents in clinical development.

Theuretzbacher U, Bush K, Harbarth S, Paul M, Rex JH, Tacconelli E, Thwaites GE. Theuretzbacher U, et al. Among authors: bush k. Nat Rev Microbiol. 2020 May;18(5):286-298. doi: 10.1038/s41579-020-0340-0. Epub 2020 Mar 9. Nat Rev Microbiol. 2020. PMID: 32152509 Review.

2

Tackling antibiotic resistance.

Bush K, Courvalin P, Dantas G, Davies J, Eisenstein B, Huovinen P, Jacoby GA, Kishony R, Kreiswirth BN, Kutter E, Lerner SA, Levy S, Lewis K, Lomovskaya O, Miller JH, Mobashery S, Piddock LJ, Projan S, Thomas CM, Tomasz A, Tulkens PM, Walsh TR, Watson JD, Witkowski J, Witte W, Wright G, Yeh P, Zgurskaya HI. Bush K, et al. Nat Rev Microbiol. 2011 Nov 2;9(12):894-6. doi: 10.1038/nrmicro2693. Nat Rev Microbiol. 2011. PMID: 22048738 Free PMC article. Review.

3

Forgotten antibiotics: an inventory in Europe, the United States, Canada, and Australia.

Pulcini C, Bush K, Craig WA, Frimodt-Møller N, Grayson ML, Mouton JW, Turnidge J, Harbarth S, Gyssens IC; ESCMID Study Group for Antibiotic Policies. Pulcini C, et al. Among authors: bush k. Clin Infect Dis. 2012 Jan 15;54(2):268-74. doi: 10.1093/cid/cir838. Clin Infect Dis. 2012. PMID: 22198992 Review.

4

Epidemiology of β-Lactamase-Producing Pathogens.

Bush K, Bradford PA. Bush K, et al. Clin Microbiol Rev. 2020 Feb 26;33(2):e00047-19. doi: 10.1128/CMR.00047-19. Print 2020 Mar 18. Clin Microbiol Rev. 2020. PMID: 32102899 Free PMC article. Review.

5

What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles.

Bush K, Page MGP. Bush K, et al. J Pharmacokinet Pharmacodyn. 2017 Apr;44(2):113-132. doi: 10.1007/s10928-017-9506-4. Epub 2017 Feb 4. J Pharmacokinet Pharmacodyn. 2017. PMID: 28161807 Review.

6

Interplay between β-lactamases and new β-lactamase inhibitors.

Bush K, Bradford PA. Bush K, et al. Nat Rev Microbiol. 2019 May;17(5):295-306. doi: 10.1038/s41579-019-0159-8. Nat Rev Microbiol. 2019. PMID: 30837684 Review.

7

Epidemiological expansion, structural studies, and clinical challenges of new β-lactamases from gram-negative bacteria.

Bush K, Fisher JF. Bush K, et al. Annu Rev Microbiol. 2011;65:455-78. doi: 10.1146/annurev-micro-090110-102911. Annu Rev Microbiol. 2011. PMID: 21740228 Review.

8

Investigational antimicrobial agents of 2013.

Pucci MJ, Bush K. Pucci MJ, et al. Among authors: bush k. Clin Microbiol Rev. 2013 Oct;26(4):792-821. doi: 10.1128/CMR.00033-13. Clin Microbiol Rev. 2013. PMID: 24092856 Free PMC article. Review.

9

Discovery and development of new antibacterial agents targeting Gram-negative bacteria in the era of pandrug resistance: is the future promising?

Page MG, Bush K. Page MG, et al. Among authors: bush k. Curr Opin Pharmacol. 2014 Oct;18:91-7. doi: 10.1016/j.coph.2014.09.008. Epub 2014 Sep 29. Curr Opin Pharmacol. 2014. PMID: 25277839 Review.

10

Taking inventory: antibacterial agents currently at or beyond phase 1.

Bush K, Macielag M, Weidner-Wells M. Bush K, et al. Curr Opin Microbiol. 2004 Oct;7(5):466-76. doi: 10.1016/j.mib.2004.08.013. Curr Opin Microbiol. 2004. PMID: 15451501 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

641 results

Search Page